Table 1.
Prognostic and clinical factors and their influence on therapeutic response in metastatic melanoma patients.
| Prognostic factor | Value | Immunotherapy*58,59 | BRAF + MEK inhibitors60,61 |
|---|---|---|---|
| LDH | Normal | 1-year OS: 72% | 2-year PFS: 39–40% |
| >ULN | 1-year OS: 44% | 2-year PFS: 14% | |
| >2× ULN | 2-year PFS: 6% | ||
| 3-year PFS: 0% | |||
| Sum of lesion diameters (SLD) | ≤44 mm | 3-year PFS: 52% | |
| >44 mm | 3-year PFS: 0% | ||
| <66 mm | 3-year PFS: 43% | ||
| ≥66 mm | 3-year PFS: 27% | ||
| 102 mm | ORR: 42% | ||
| ≥102 mm | ORR: 24% |
ULN, upper limit of normal; OS, overall survival; PFS, progression-free survival; ORR, overall response rate.
*
Immunotherapy data include both BRAF wild-type and V600-mutant patients.